

NDA 020131/S-037

SUPPLEMENT APPROVAL

Bracco Diagnostics Inc. Attention: Patrice Marchildon Senior Director, North America Regulatory Affairs 259 Prospect Plains Road Building H Monroe Township, NJ 08831

Dear Ms. Marchildon:

Please refer to your Supplemental New Drug Application (sNDA) dated and received June 2, 2022, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ProHance (gadoteridol injection).

This "Changes Being Effected" supplemental new drug application provides for labeling changes as specified in the Agency's supplement request letter dated May 5, 2022.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in MS Word format,

U.S. Food & Drug Administration Silver Spring, MD 20993 www.fda.gov NDA 020131/S-037 Page 2

that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Grecia C. Edwards, Regulatory Business Process Manager, at (240) 402 - 1773.


Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, PhD Branch Chief, B1 Division of Post-Marketing Activities I Office of Lifecycle Drug Products Office of Pharmaceutical Quality Center for Drug Evaluation and Research

Enclosure:

Content of Labeling



Digitally signed by Ramesh Raghavachari Date: 11/28/2022 01:50:39PM GUID: 502d0913000029f375128b0de8c50020